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 6 
Abstract 7 
Objective To compare the effect of propofol and alfaxalone on laryngeal motion under 8 
a light plane of anaesthesia in non-brachycephalic and brachycephalic dogs 9 
anaesthetized for non-emergency procedures. 10 
Study design Prospective, randomized clinical trial. 11 
Animals A total of 48 client-owned dogs (24 non-brachycephalic and 24 12 
brachycephalic). 13 
Methods A standardized premedication of methadone (0.2 mg kg-1) and acepromazine 14 
(0.01 mg kg-1) was administered intramuscularly. Dogs were randomly assigned to be 15 
induced with increments of propofol (1 – 4 mg kg-1) or alfaxalone (0.5 – 2 mg kg-1). 16 
Laryngeal assessment was performed under a light plane of anaesthesia by a surgeon 17 
(GTH) who was unaware of the induction protocol. Laryngeal movement was assessed 18 
as either being present when abduction of the laryngeal cartilages upon inspiration was 19 
identified or absent when abduction was not recognized. Simultaneously, a 60-second 20 
video was recorded. The same surgeon (GTH) and an additional surgeon (NK) re-21 
evaluated the videos one month later. Categorical comparisons were studied using Chi 22 
squared and Fisher’s Exact tests where appropriate. Pair-wise evaluation of agreement 23 
between scorers was undertaken with the kappa statistic (κ).  24 
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Results There were no significant differences (p > 0.05) identified between the 25 
presence or absence of laryngeal motion between dogs administered propofol or 26 
alfaxalone, as well as when analysing non-brachycephalic and brachycephalic dogs 27 
separately. The majority of dogs (>75%) maintained some degree of laryngeal motion 28 
with both protocols. Agreement between assessors was excellent (κ = 0.822).  29 
Conclusions Alfaxalone maintained laryngeal motion similarly to propofol in non-30 
brachycephalic and brachycephalic dogs.  31 
Clinical relevance Both agents would appear appropriate for allowing assessment of 32 
laryngeal motion in non-brachycephalic and brachycephalic dogs. The assessment 33 
technique of subjective evaluation of laryngeal motion via per oral laryngoscopy under 34 
a light plane of anaesthesia produced consistent results amongst assessors, regardless of 35 
the induction agent used.  36 
Keywords alfaxalone, dog, propofol, laryngeal paralysis, larynogoscopy 37 
 38 
Introduction 39 
Normal laryngeal motion, which is used as an indicator for laryngeal function, is 40 
demonstrated by the abduction of the arytenoid cartilages during inhalation and passive 41 
relaxation during exhalation (Gross et al. 2002). Peroral laryngoscopy under a light 42 
plane of anaesthesia is the most widely used clinical method for interpretation of 43 
laryngeal motion in dogs with 95% interobserver agreement (Broome et al. 2000; 44 
Radlinsky et al. 2009; Smith 2000). The ideal anaesthetic protocol should provide 45 
relaxation of the jaw muscles, maintenance of laryngeal reflexes and minimal 46 
respiratory depression (McKeirnan et al. 2014). 47 
 48 
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A previous study by Jackson et al. (2004) concluded that intravenous thiopental given to 49 
effect was the best choice for assessing laryngeal motion in dogs. Significantly greater 50 
arytenoid motion was demonstrated after thiopental administration when compared with 51 
other anaesthetic protocols (propofol, ketamine, diazepam and acepromazine). Although 52 
thiopental remains a useful agent in veterinary anaesthesia, it is no longer licensed in 53 
veterinary species and has therefore been largely replaced by propofol (Clarke et al. 54 
2014).  55 
 56 
Alfaxalone is a synthetic neurosteroid that at high concentrations acts as a direct agonist 57 
of the GABAA receptor (Berry 2015). It is used in veterinary practice as an induction 58 
agent for anaesthesia. Minimal studies regarding this drug’s effect on laryngeal motion 59 
and function have been published up until now, especially in a clinical setting. A paper 60 
by Smalle et al. (2017) concluded that there was no significant difference in the total 61 
number of arytenoid motions after administration of thiopental, propofol or alfaxalone 62 
in six research dogs. Nelissen et al. (2012a) also identified no significant difference in 63 
arytenoid cartilage motion evaluating healthy cats using video laryngoscopy after 64 
administration of alfaxalone, propofol or midazolam/ketamine. On the other hand, a 65 
paper looking at the efficacy and safety of alfaxalone in humans (Monagle et al. 2015) 66 
identified significantly less airway obstruction and therefore better airway patency after 67 
alfaxalone administration compared to propofol.  68 
 69 
Laryngeal paralysis is a common airway disorder in large breed dogs (Holt & Brockman 70 
1994; Burbridge 1994) that is diagnosed via subjective airway assessment. It is vital to 71 
use an induction agent that maintains laryngeal motion in suspect cases to increase 72 
objectivity and accuracy of the assessment method. Moreover, an anaesthetic agent that 73 
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maintains laryngeal motion will provide a patent rima glottidis during induction 74 
allowing persistent oxygen flow. This may prove safer, especially in breeds where 75 
difficult intubation is more likely to occur. Brachycephalic breeds often have congenital 76 
defects such as narrowed nares, an overlong soft palate, tracheal hypoplasia and 77 
excessive laryngeal tissue (De Lorenzi et al. 2009)]. These defects impose a much 78 
higher risk of airway occlusion and secondary hypoxia especially during induction of 79 
anaesthesia, before successful intubation has occurred. 80 
 81 
The main aim of this study was to assess whether laryngeal motion was present or 82 
absent under a light plane of anaesthesia after injecting either alfaxalone or propofol. 83 
This was evaluated in a cohort of non-brachycephalic and brachycephalic dogs, prior to 84 
routine surgical procedures performed in a university referral hospital. The second aim 85 
of this study was to evaluate the degree of inter-observer variability when using peroral 86 
laryngoscopy for assessment of laryngeal motion. 87 
 88 
Methods and Materials 89 
Animals 90 
The study was approved by the Ethics and Welfare Committee of the Royal Veterinary 91 
College (URN 2016 1603) and informed owner consent was obtained.  A total of 48 92 
client-owned dogs were included (24 non-brachycephalic and 24 brachycephalic dogs) 93 
all of which were admitted to the Queen Mother Hospital requiring general anaesthesia 94 
for non-emergency procedures. This sample size was chosen as it was deemed an 95 
achievable number of dogs to enrol onto the study within the time frame that it could be 96 
performed. The time frame was pre-determined by the ethical committee and surgeon 97 
availability. On the basis of a full physical examination and the medical history, all non-98 
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brachycephalic dogs were considered to be American Society of Anaesthesiologists 99 
(ASA) grade I – II and all the brachycephalic dogs were considered to be ASA grade ≤ 100 
III (Tranquilli and Grimm 2015). Dogs were excluded from the study if they were 101 
classified as ASA grade ≥ III (non-brachycephalic) or ≥ IV (brachycephalic), or if they 102 
presented with a problem that may impact the nerves relating to the function of the 103 
larynx, such as laryngeal paralysis. The dogs were randomly allocated to one of two 104 
groups by blindly drawing a number out of an envelope. Anaesthesia was induced with 105 
propofol in group P (n = 24: 12 non-brachycephalic, 12 brachycephalic) and with 106 
alfaxalone in group A (n = 24: 12 non-brachycephalic, 12 brachycephalic).  107 
Protocol 108 
Premedication consisted of acepromazine (ACP injection; Novartis, UK) 0.01 mg kg-1 109 
and methadone (Comfortan; Dechra, UK) 0.2 mg kg-1 injected intramuscularly (IM) into 110 
the cervical epaxial musculature 30 minutes prior to induction. The premedication was 111 
administered in a quiet preparation room. Immediately prior to induction, an 112 
intravenous (IV) catheter was placed in a peripheral vein and a sedation score using a 113 
simple descriptive scale ranging from 0 (no change from pre-sedation behaviour) to  3 114 
(very heavily sedated, unable to walk) (Table 1) was assigned. 115 
The maximum dose of each induction agent (propofol 4 mg kg-1 or alfaxalone 116 
 2 mg kg-1) were calculated for each animal, drawn up and kept hidden. Each drug’s 117 
dose was chosen following the data sheets’ recommendation in premedicated dogs. 118 
Estimated lean body weight was used in severely overweight dogs. Prior to the arrival 119 
of the assessor, a drape was placed over the IV catheter site to allow the induction agent 120 
to be concealed from everyone in the room apart from the injector.  121 
Propofol (Propoflo; Abbott Animal Health, UK) or alfaxalone (Alfaxan; Jurox, 122 
Australia) were administered in quarterly increments IV until a light plane of 123 
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anaesthesia was achieved; characterized by easy visual access to the larynx, persistence 124 
of breathing and the maintenance of a gag reflex. Each increment was administered by 125 
hand over 10 seconds with a 20-second pause before the next increment was injected. 126 
An experienced board certified small animal specialist surgeon (GTH) was present at 127 
each induction and assessed the airway using peroral laryngoscopy. The laryngeal exam 128 
was performed by placing the dog in sternal recumbency, holding open the upper jaw to 129 
expose the oral cavity, pulling the tongue forward and depressing the base of the tongue 130 
just below the epiglottis (epiglottic vallecular) using a laryngoscope. If the plane of 131 
anaesthesia was deemed too deep by the surgeon (GTH) for immediate laryngeal 132 
assessment, the dog’s oral cavity was closed and flow by oxygen was provided whilst 133 
being under constant observation from the anaesthetist and surgeon. As soon as the 134 
respiration rate increased, the surgeon (GTH) would attempt another laryngeal exam 135 
ensuring the return of the gag reflex before beginning the assessment. In each dog 136 
laryngeal motion was simply assessed as being either present or absent. This was 137 
determined by the degree of arytenoid abduction during inspiration and the amount of 138 
rima glottidis observed (Table 2). 139 
During the assessment, a short (30 – 60 second) video was also made of the larynx 140 
using an iPhone 6s over at least 4 respiratory cycles, which was to be used later for re-141 
evaluation of laryngeal motion. Following this, the dog was given more induction agent 142 
to allow intubation and was no longer followed for the purposes of the study. The 143 
dosages of induction agent administered to allow laryngeal assessment and intubation 144 
were recorded as well as any complication that occurred. 145 
 146 
One month after the last assessment, all the videos were reassessed for the presence or 147 
absence of laryngeal motion by the same surgeon (GTH) as well as another board 148 
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certified small animal surgery specialist (NK). During reassessment of the videos, a 149 
third intermediate answer category (presence of minimal laryngeal motion) (Table 2) 150 
was added. This third category was added to refine the grading system and potentially 151 
detect more subtle differences between induction agents as during the data collection 152 
process varying degrees of laryngeal movement were detected. The videos were 153 
evaluated separately by each surgeon. A random number shown at the beginning of 154 
each video was used to identify each dog. Following this, a final collaborative 155 
assessment was made between the two surgeons who agreed on one assessment 156 
category for each dog. 157 
 158 
Statistical analysis 159 
Data were analysed using commercial software (SPSS for Mac 2015 version 23; IBM, 160 
United States). Normality of the interval variables (weight, age, dose of induction agent 161 
required for laryngeal assessment and dose of induction agent required for intubation) 162 
was assessed graphically and by using the Shapiro-Wilk test. None of the data were 163 
normally distributed and therefore results were reported as median (range). Categorical 164 
comparisons (presence or absence of laryngeal motion) were studied using Chi square 165 
and Fishers Exact tests as appropriate. Pair-wise evaluation of agreement between 166 
scorers in the evaluation of laryngeal motion using the scale with categories was 167 
undertaken with the kappa statistic. Results were considered significant when p ≤ 0.05. 168 
 169 
Results 170 
A total of 48 dogs (24 non-brachycephalic; 24 brachycephalic) were recruited for this 171 
project. All animals completed the study (Fig. 1). The demographic data of the animals 172 
did not differ significantly between the two groups (Table 3). The dose of injectable 173 
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anaesthetic that allowed laryngeal assessment in all dogs was 1.9 (0.9 – 5.1) mg kg-1 for 174 
group P and 0.5 (0.2 – 1.9) mg kg -1 for group A. The dose of injectable anaesthetic 175 
agent to allow intubation in all dogs was 3.0 (1.1 – 6.9) mg kg-1 for group P and 2.0 (0.5 176 
– 3.0) mg kg-1 for group A. 177 
 178 
Overall the maintenance of some degree of laryngeal motion was identified in a large 179 
majority of cases regardless of the induction agent used or whether the dog was non-180 
brachycephalic or brachycephalic. During the initial assessment (Fig. 2), 75% of dogs 181 
were evaluated as having laryngeal motion present. During the collaborative assessment 182 
(Fig. 3) after the addition of the third scoring category, 87.5% of dogs were assessed as 183 
having some degree of laryngeal motion. 184 
 185 
There were no significant differences identified between the presence or absence of 186 
laryngeal motion in all dogs collectively after either propofol or alfaxalone was 187 
administered, as well as when analysing non-brachycephalic and brachycephalic dogs 188 
separately, in any of the assessments carried out. P values calculated for the initial 189 
assessment made by the first surgeon (GTH) - All dogs: p = 0.63, non-brachycephalic: 190 
p = 0.5, brachycephalic: p = 0.653. P values calculated for the reassessment made by 191 
the first surgeon (GTH) – All dogs: p = 0.571, non-brachycephalicl: p = 0.879, 192 
brachycephalic: p = 0.325. P values calculated for the reassessment made by the 193 
second surgeon (NK) - All dogs: p = 0.607, non-brachycephalic: p = 0.717, 194 
brachycephalic: p = 0.154. There were no statistical differences found between group P 195 
and group A in respect to the presence or absence of laryngeal motion in the final 196 
collaborative assessment made between the two surgeons (GTH, NK) (All dogs: p = 197 
0.371, non-brachycephalic: p = 0.879, brachycephalic: p = 0.593). 198 
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 199 
Agreement between the surgeons for assessment of laryngeal motion using the scale 200 
with three categories was rated as excellent [kappa statistic (κ) = 0.822] displaying very 201 
good inter-rater reliability for the assessment method.  202 
 203 
In total, three complications were noted during the study. One occurred in group P 204 
which involved pain on injection of the induction agent. Two occurred in group A in 205 
which excitation was experienced during injection of the induction agent in both dogs. 206 
These complications were considered mild and the experiment was continued in all of 207 
these dogs without any intervention implemented.  208 
Discussion 209 
There was no significant difference found between the use of either propofol or 210 
alfaxalone on the maintenance of laryngeal motion in any of the assessments carried 211 
out. This result is consistent with the results of Smalle et al. (2017). On the contrary, 212 
Monagle et al. (2015) found that airway patency was maintained better with alfaxalone 213 
compared to propofol in humans. The explanation given for the difference in airway 214 
patency is attributed to the distribution of GABAA subunits, targeted by alfaxalone and 215 
propofol. Previous work has shown that there is a relative lack of GABA subunits 216 
targeted by neurosteroids in the human brainstem compared with the cerebral cortex 217 
(Persohn et al. 1992; Wegner et al. 2007) and therefore alfaxalone has little activity in 218 
the brainstem (Thornton et al. 1986). The vagus nerve originates from the brainstem and 219 
is ultimately responsible for the control of the intrinsic muscles of the larynx via the 220 
recurrent and caudal laryngeal nerve (Hermanson & Evans 1993). However, 221 
information regarding the distribution of specific GABA subunits in other species 222 
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including dogs is limited and therefore explaining the difference in the results between 223 
the two studies can only be done by speculation. 224 
 225 
Other factors that may have affected laryngeal motion in this study include the 226 
premedication given and the speed of administration of the injectable anaesthetic agent. 227 
The use of acepromazine as part of the anaesthetic protocol when assessing laryngeal 228 
motion has both been advocated and advised against. Jackson et al. (2004) identified 229 
that arytenoid motion was significantly less with thiopental and acepromazine than with 230 
thiopental alone, suggesting that ACP depresses arytenoid motion. However, the doses 231 
used (0.05 mg kg-1) were five times higher than those used in the current study. 232 
Moreover, numerous sources actually suggest the inclusion of low dose ACP in the 233 
premedication before laryngeal assessment because of its anxiolytic effect (Dugdale 234 
2010; Murrell 2016); which decreases stress and therefore the risk of airway occlusion. 235 
This was deemed particularly important for the brachycephalic cohort in this study.  236 
 237 
Achieving the optimum level of anaesthesia for laryngeal assessment can be difficult, 238 
with the speed of administration of the injectable anaesthetic agent contributing heavily 239 
to this. The preservation of the respiratory cycle is necessary to determine accurate 240 
arytenoid motion. Rapid IV injection (less than 5 seconds) of propofol and alfaxalone 241 
commonly resulted in post-induction apnoea (Amengual et al. 2013). In this study, the 242 
anaesthetic agent was given slowly to effect in incremental doses. Another possible 243 
method of administration would have been via a constant rate infusion using a syringe 244 
driver. This method, in theory, should titrate the injectable anaesthetic agent more 245 
precisely allowing the desired level of anaesthesia for laryngeal assessment to be 246 
captured instantly. However, when this method was used in cats receiving different 247 
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anaesthetic agents for assessing laryngeal motion (Nelissen et al. 2012a), assessment 248 
and intubation doses in all the cats were the same suggesting that the appropriate point 249 
at which to assess had already been surpassed. From a practical point of view, the 250 
method of administration performed in this study required less equipment and is more 251 
reflective of common clinical practice. 252 
 253 
Both the use of ACP as part of the premedication and the incremental injection of the 254 
chosen anaesthetic agent in this study, are factors that in theory would reduce laryngeal 255 
motion. Therefore, it would be expected to identify more dogs with the absence of 256 
laryngeal motion than truly present. However, despite these factors the majority of dogs 257 
(>75%) maintained some degree of laryngeal motion in both the propofol and 258 
alfaxalone group, suggesting that they had minimal impact. Moreover, this result 259 
supports the use of either injectable anaesthetic agent for laryngeal assessment. 260 
 261 
A potential limitation in this study was the use of a scoring system with minimal 262 
categories. Smalle et al. (2017) used a much more extensive scoring system comprising 263 
of four categories each with two subcategories. Although not validated, the scoring 264 
system utilized in this study was adopted from previous studies and adjusted using the 265 
grading system for laryngeal function in non-sedated horses (Gross et al. 2002; 266 
Robinson 2004; McKeirnan et al. 2014). While no significant difference was found in 267 
that study between thiopentone, propofol and alfaxalone, with the much larger subject 268 
numbers used in the current study, a potential difference between anaesthetic agents and 269 
laryngeal motion may have been detected.  270 
 271 
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The third intermediate category (minimal laryngeal movement) for the reassessment of 272 
the airways was not part of the original study protocol. However, after the initial data 273 
collection it was apparent that some dogs had very obvious laryngeal motion and some 274 
had minimal. The justification to implement this additional category was to potentially 275 
identify a significant difference between obvious and subtle laryngeal motion and 276 
whether this could be attributed to either anaesthetic agent, possibly providing some 277 
clinical benefit. Due to this alteration, intra-observer variability could not be 278 
determined.  279 
 280 
Another limitation of the study was that thiopental was not used as a comparative 281 
induction agent. Thiopental has historically been considered the best choice for the 282 
assessment of laryngeal motion (Jackson et al. 2004) and therefore novel induction 283 
agents should be compared to it. However, no licenced thiopental product is available 284 
for veterinary patients in the EU or UK, therefore its use could not be justified in 285 
clinical patients. Moreover, the fact that thiopental is no longer available gives more 286 
reason to find a comparable, accessible alternative for laryngeal assessment. 287 
 288 
To the knowledge of the authors, this is the first study to assess the effect of different 289 
anaesthetic agents on laryngeal motion in brachycephalic as well as non-brachycephalic 290 
dogs. Therefore, an appropriate assessment technique for evaluating laryngeal motion in 291 
a cohort of dogs with such a grossly altered respiratory anatomy has not been described 292 
before and there may be other factors that should be taken into account when trying to 293 
make an accurate assessment.  For example, we know that a majority of brachycephalic 294 
dogs present with some degree of laryngeal collapse (Monet and Tobias 2012). The 295 
effect of laryngeal collapse on laryngeal motion has not been reported although the 296 
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incident of both pathologies co-occurring has been described (Nelissen and White 297 
2012b). The degree of laryngeal collapse was not recorded in this study; therefore, it is 298 
difficult to determine whether this variable had any impact on the results obtained. 299 
Future studies could focus on specific laryngeal assessment in the brachycephalic 300 
population, the impact of laryngeal collapse on laryngeal motion and if our current 301 
assessment measures for laryngeal motion are even applicable to brachycephalic dogs as 302 
they have so many airway malformations.  303 
 304 
Conclusion Alfaxalone maintains laryngeal motion similarly when compared to 305 
propofol in non-brachycephalic and brachycephalic dogs. Agreement between assessors 306 
was excellent.  307 
 308 
 309 
 310 
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Table 1 Description of scoring categories used to assess degree of sedation after 395 
premedication with acepromazine 0.01 mg kg-1 and methadone 0.2 mg kg-1 396 
intramuscularly in 48 dogs. 397 
 398 
Table 2 Descriptors used for assessing laryngeal motion. 399 
 400 
Table 3 Demographic and other data of all dogs included in this study. Anaesthesia was 401 
induced with either propofol (0.9 – 6.9 mg kg -1) (group P all dogs, n = 24; group P non-402 
brachycephalic dogs, n = 12; group P brachycephalic dogs, n = 12) or alfaxalone (0.2 – 403 
3.0 mg kg -1) (group A all dogs, n = 24; group A non-brachycephalic dogs, n = 12; 404 
group A brachycephalic dogs, n = 12). 405 
 406 
Figure 1 CONSORT flow diagram for this study. Dogs were randomly divided into two 407 
groups: group P, in which laryngeal motion was evaluated after the administration of 408 
propofol; and group A, in which laryngeal motion was evaluated after the 409 
administration of alfaxalone. 410 
 411 
Figure 2 Number of dogs in each scoring category (x axis) during the initial assessment 412 
of laryngeal motion after receiving either propofol or alfaxalone (y axis). A ‘Present’ 413 
assessment equates to the maintenance of laryngeal motion and an ‘absent’ assessment 414 
equates to the absence of laryngeal motion. 415 
 416 
Figure 3 Number of dogs in each scoring category (x axis) during the collaborative re-417 
assessment of laryngeal motion after receiving either propofol or alfaxalone (y axis). A 418 
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‘present’ assessment equates to the obvious maintenance of laryngeal motion, a 419 
‘Minimal’ assessment equates to marginal laryngeal motion and an ‘absent’ assessment 420 
equates to the absence of laryngeal motion. 421 
 422 
 423 
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Tables  
 
Table 1 Description of scoring categories for degree of sedation after premedication with 
acepromazine 0.01 mg kg-1 and methadone 0.2 mg kg-1 intramuscularly in 48 dogs. 
Category Description 
0 No change from pre-sedation behaviour 
1 Mild sedation (with head slightly 
lowered) 
2 Moderate sedation (with head lowered 
and ataxia) 
3 Very heavily sedated, unable to walk 
 
 
Table 2 Descriptors used for assessing laryngeal motion.  
Assessment answer Description 
Obvious laryngeal motion present Clear abduction of the arytenoid 
cartilages during inspiration. Maximal 
rima glottidis observed. Maintenance of 
laryngeal motion. 
Absence of laryngeal motion  No obvious arytenoid abduction during 
inspiration. Minimal rima glottidis 
observed. Laryngeal motion not 
maintained. 
Minimal laryngeal motion present Mild to moderate degree of abduction of 
the arytenoid cartilages during 
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inspiration. Moderate rima glottidis 
observed. Maintenance of laryngeal 
motion. 
 
 
Table 3 Demographic and other data of all the dogs in this study. Anaesthesia was induced 
with either propofol (0.9 – 6.9 mg kg -1) (group P all dogs, n = 24; group P non-
brachycephalic dogs, n = 12; group P brachycephalic dogs, n = 12) or alfaxalone (0.2 – 3.0 
mg kg -1) (group A all dogs, n = 24; group A non-brachycephalic dogs, n = 12; group A 
brachycephalic dogs, n = 12). 
 Dogs Group P Group A 
Sex Female 10 8 
Male 14 16 
Age (months) All 52.5 (11 – 
167) 
51.5 (7 – 165) 
Non-brachycephalic 69.5 (11 – 
167) 
51.5 (7 – 104) 
Brachycephalic 38.5 (12 – 
119) 
46 (11 – 165) 
Weight (kg) All 11.1 (5.8 – 
34.7) 
11.4 (2.2 – 46.0) 
Non-brachycephalic 16.5 (5.8 – 
34.7) 
26.8 (5.0 – 46.0) 
Brachycephalic 9.0 (6.2 – 
18.8) 
10.2 (2.2 – 22.0) 
Sedation score  All 1 (0 – 3) 2 (0 – 3) 
Non-brachycephalic 1 (0 – 3) 2 (1 – 3) 
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Brachycephalic 1(0 – 3) 2 (1 – 3) 
Dose of drug to allow 
laryngeal assessment 
(mg kg -1) 
All 1.9 (0.9 – 
5.1) 
0.5 (0.2 – 1.9) 
Non-brachycephalic 1.9 (0.9 – 
5.0) 
0.5 (0.4 – 1.0) 
Brachycephalic 1.9(0.9 – 
5.1) 
0.5 (0.2 – 1.9) 
Dose of drug to allow 
intubation (mg kg -1) 
All 3.0 (1.1 – 
6.9) 
2.0 (0.5 – 3.0) 
Non-brachycephalic 3.0(1.1 – 
6.9) 
1.0 (0.7 – 3.0) 
Brachycephalic 3.0 (1.1 – 
5.1) 
1.0 (0.5 – 1.9) 
Number of 
complications 
All 1 2 
Non-brachycephalic 1 1 
Brachycephalic 0 1 
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